<DOC>
	<DOCNO>NCT00312494</DOCNO>
	<brief_summary>3-week study evaluate efficacy safety ziprasidone either lithium divalproex acutely manic subject</brief_summary>
	<brief_title>3-week Study Evaluate Efficacy Safety Ziprasidone With Either Lithium Divalproex Acutely Manic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Subjects must primary diagnosis Bipolar I Disorder , recent episode manic ( 296.4x ) , mixed ( 296.6x ) define Diagnostic Statistical Manual Mental Disorders Text Revision ( DSMIV TR ) determine Mini International Neuropsychiatric Interview ( MINI ) . At screen baseline ( within 12 hour prior first dose doubleblind medication ) subject must Young Mania Rating Scale score 18 high . Subjects must actively receive lithium divalproex bipolar disorder order consider study . Subjects Diagnostic Statistical Manual Mental Disorders IV Text Revision ( DSMIV TR ) diagnosis schizophrenia ( 295.XX ) , schizoaffective disorder ( 295.70 ) , schizophreniform disorder ( 295.40 ) , delusional disorder ( 297.1 ) , psychotic disorder otherwise specify ( NOS ) ( 298.9 ) . Subjects DSMIVTR Axis I Axis II disorder ( addition Bipolar I disorder ) ineligible comorbid condition clinically unstable , require treatment , primary focus treatment within 6month period prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>